Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX4 PET Imaging in Head and Neck Cancer
NCT01213030Phase 2Completed
- Sponsor
- Siemens AG
- Start
- Jun 2009
- Primary completion
- Jan 2010
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label trial of Flortanidazole F-18 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Siemens AG. Primary endpoint: Efficacy of HX4 at 6 months. Started Jun 2009; status: completed.
02
Drugs
Flortanidazole F-18
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01213030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213030.